- Home
- EWCZ vs ENGN Comparison
EWCZ vs ENGN Comparison
Compare EWCZ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- ENGN
- Stock Information
- Founded
- EWCZ 2004
- ENGN 1999
- Country
- EWCZ United States
- ENGN Canada
- Employees
- EWCZ N/A
- ENGN N/A
- Industry
- EWCZ Package Goods/Cosmetics
- ENGN
- Sector
- EWCZ Consumer Discretionary
- ENGN
- Exchange
- EWCZ Nasdaq
- ENGN Nasdaq
- Market Cap
- EWCZ 239.2M
- ENGN 191.1M
- IPO Year
- EWCZ 2021
- ENGN N/A
- Fundamental
- Price
- EWCZ $5.15
- ENGN $3.51
- Analyst Decision
- EWCZ Buy
- ENGN Buy
- Analyst Count
- EWCZ 7
- ENGN 7
- Target Price
- EWCZ $5.86
- ENGN $23.29
- AVG Volume (30 Days)
- EWCZ 544.0K
- ENGN 76.2K
- Earning Date
- EWCZ 08-13-2025
- ENGN 09-09-2025
- Dividend Yield
- EWCZ N/A
- ENGN N/A
- EPS Growth
- EWCZ N/A
- ENGN N/A
- EPS
- EWCZ 0.21
- ENGN N/A
- Revenue
- EWCZ $216,469,000.00
- ENGN N/A
- Revenue This Year
- EWCZ N/A
- ENGN N/A
- Revenue Next Year
- EWCZ $2.17
- ENGN N/A
- P/E Ratio
- EWCZ $25.09
- ENGN N/A
- Revenue Growth
- EWCZ N/A
- ENGN N/A
- 52 Week Low
- EWCZ $2.72
- ENGN $2.65
- 52 Week High
- EWCZ $10.28
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- EWCZ 39.96
- ENGN 48.11
- Support Level
- EWCZ $5.44
- ENGN $3.25
- Resistance Level
- EWCZ $5.84
- ENGN $3.98
- Average True Range (ATR)
- EWCZ 0.22
- ENGN 0.26
- MACD
- EWCZ -0.09
- ENGN -0.00
- Stochastic Oscillator
- EWCZ 1.95
- ENGN 54.37
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.